Holen Sie sich die Stockscreener-App
7.63
0.26%
-0.02
Handel nachbörslich:
7.63
Schlusskurs vom Vortag:
$7.65
Offen:
$7.55
24-Stunden-Volumen:
527.27K
Relative Volume:
1.02
Marktkapitalisierung:
$412.72M
Einnahmen:
$2.81M
Nettoeinkommen (Verlust:
$-97.34M
KGV:
-4.8291
EPS:
-1.58
Netto-Cashflow:
$-91.47M
1W Leistung:
-12.80%
1M Leistung:
-17.42%
6M Leistung:
+50.49%
1J Leistung:
+119.25%
1-Tages-Spanne:
$7.27
$7.71
1-Wochen-Bereich:
$7.27
$9.47
52-Wochen-Spanne:
$2.315
$10.11
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Firmenname
Fulcrum Therapeutics Inc
Sektor
Branche
Telefon
617-651-8851
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie FULC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
7.63 | 414.01M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-29 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Herabstufung | Stifel | Buy → Hold |
| 2024-09-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-09-25 | Eingeleitet | Goldman | Neutral |
| 2023-08-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Hochstufung | Stifel | Hold → Buy |
| 2023-05-04 | Herabstufung | Goldman | Buy → Neutral |
| 2023-03-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2023-02-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Eingeleitet | Goldman | Buy |
| 2022-03-08 | Eingeleitet | Oppenheimer | Outperform |
| 2022-03-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2020-10-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2019-10-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-08-12 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum Therapeutics (NASDAQ: FULC) grants inducement options; 10-year, 4-year vesting - Stock Titan
How Fulcrum Therapeutics Inc. stock responds to policy changes2025 Key Lessons & Step-by-Step Trade Execution Guides - newser.com
Tick level data insight on Fulcrum Therapeutics Inc. volatilityWatch List & Safe Capital Investment Plans - newser.com
Multi asset correlation models including Fulcrum Therapeutics Inc.July 2025 Update & Real-Time Chart Pattern Alerts - newser.com
Will Fulcrum Therapeutics Inc. stock gain from strong economyCEO Change & High Return Trade Opportunity Guides - newser.com
Statistical indicators supporting Fulcrum Therapeutics Inc.’s strengthWeekly Stock Report & Fast Moving Stock Watchlists - newser.com
Identifying reversal signals in Fulcrum Therapeutics Inc.Quarterly Earnings Report & Technical Entry and Exit Alerts - newser.com
Is Fulcrum Therapeutics Inc. stock attractive for passive investors2025 Market Overview & Precise Swing Trade Entry Alerts - newser.com
Why Fulcrum Therapeutics Inc. stock is in analyst buy zone2025 Performance Recap & Growth-Oriented Investment Plans - newser.com
Fulcrum Therapeutics (FULC) Receives Buy Rating and $20 Price Target from Stifel - GuruFocus
Why Fulcrum Therapeutics Inc. stock is rated strong buy2025 Pullback Review & Weekly Watchlist of Top Performers - fcp.pa.gov.br
Will Fulcrum Therapeutics Inc. continue its uptrendJuly 2025 Setups & High Accuracy Investment Signals - newser.com
Can Fulcrum Therapeutics Inc. stock maintain growth trajectory2025 Growth vs Value & Capital Protection Trade Alerts - fcp.pa.gov.br
Can Fulcrum Therapeutics Inc. stock resist sector downturns2025 Pullback Review & Reliable Price Breakout Alerts - newser.com
Published on: 2025-11-06 04:16:47 - newser.com
Will Fulcrum Therapeutics Inc. stock beat EPS estimatesJuly 2025 Review & Real-Time Chart Breakout Alerts - newser.com
How to track smart money flows in Fulcrum Therapeutics Inc.Market Risk Summary & Capital Protection Trade Alerts - newser.com
Fulcrum Therapeutics Inc. stock outlook for YEAR2025 Breakouts & Breakdowns & Safe Capital Allocation Plans - newser.com
Published on: 2025-11-06 02:38:22 - newser.com
Is Fulcrum Therapeutics Inc. stock positioned for digital transformationPortfolio Gains Summary & Risk Adjusted Buy and Sell Alerts - fcp.pa.gov.br
How to build a dashboard for Fulcrum Therapeutics Inc. stockTrade Performance Summary & Verified Chart Pattern Trade Signals - newser.com
How to forecast Fulcrum Therapeutics Inc. trends using time seriesJuly 2025 Gainers & Capital Protection Trading Alerts - newser.com
What risks investors should watch in Fulcrum Therapeutics Inc. stockTreasury Yields & Smart Investment Allocation Insights - newser.com
How institutional buying supports Fulcrum Therapeutics Inc. stock2025 Technical Overview & Smart Investment Allocation Tips - newser.com
Signal strength of Fulcrum Therapeutics Inc. stock in tech scannersQuarterly Trade Report & Proven Capital Preservation Methods - newser.com
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
How sustainable is Fulcrum Therapeutics Inc. stock dividend payoutJuly 2025 Fed Impact & High Accuracy Investment Signals - newser.com
Momentum divergence signals in Fulcrum Therapeutics Inc. chart2025 Historical Comparison & Weekly Top Gainers Trade List - newser.com
Is Fulcrum Therapeutics Inc. trending in predictive chart models2025 Big Picture & Long-Term Growth Stock Strategies - newser.com
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting - The Manila Times
Fulcrum Therapeutics to Present Phase 1b PIONEER Trial Data on Pociredir for Sickle Cell Disease at ASH 2025 - Quiver Quantitative
Fulcrum (NASDAQ: FULC) to present pociredir SCD data, 12 mg and 20 mg cohorts at ASH - Stock Titan
Finanzdaten der Fulcrum Therapeutics Inc-Aktie (FULC)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.44%
0.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):